• 05:30 PM - 07:15 PM
  Strategy commission (closed session)

  KAMINLOUNGE

• 07:30 PM - 10:00 PM
  Welcome Reception

  RESTAURANT

• 07:45 PM - 08:15 PM
  Opening Lecture

  Assessment of frailty in CLL: Does it still matter in the era of targeted agents?

  V Goede

• 08:00 AM - 08:30 AM
  Check-In | Registration

• 08:30 AM - 08:45 AM
  Welcome

  B Eichhorst

• 08:45 AM - 09:00 AM
  MCL1 Copy Number Gain Is a Recurrent Mark of Venetoclax Resistance in Patients with Chronic Lymphocytic Leukemia

  C Croizier

• 09:00 AM - 09:15 AM
  Inflammatory signaling reshapes the microenvironment and determines therapeutic vulnerabilities in Richter Transformation

  C Tomasoni

• 09:15 AM - 09:30 AM
  Unearthing the dependency of the aggressive B-cell lymphoma cancer stem cell niche on CD164-CXCR4 driven adhesion interactions

  S Blakemore

• 09:30 AM - 09:45 AM
  Normal B cells in people with IGHV-unmutated MBL follow a different maturation pathway compared to people with IGHV-mutated MBL

  G Blanco

• 09:45 AM - 10:00 AM
  Forced IgD-mediated antigen uptake by chronic lymphocytic leukemia B cells overcomes T-cell exhaustion and allows enhance antigen–specific T cell activation and proliferation

  M Cardillo

• 10:00 AM - 10:15 AM
  Chronic Lymphocytic Leukemia cells drive exaggerated proximal CD3-mediated TCR signaling underlying T cell dysfunction

  C López Sánches

• 10:45 AM - 11:00 AM
  Prognostication by End-of-Treatment Lymph Node Size and Measurable Residual Disease Status – A Pooled Analysis of German CLL Study Group Phase 3 Trials

  J Stumpf

• 11:00 AM - 11:15 AM
  Linking T Cell Phenotype and Function to Clinical Outcomes in a Chronic Lymphocytic Leukemia trial (HOVON 139)

  E Camerini

• 11:15 AM - 11:30 AM
  Is Absolute Lymphocyte Count–Only Progression Clinically Relevant in CLL?

  X Wu

• 11:30 AM - 11:45 AM
  Intraclonal diversification in immunoglobulin light chain genes refines prognostication in early-stage chronic lymphocytic leukemia

  R Moia

• 11:45 AM - 12:00 PM
  Pirtobrutinib (Pirto) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): a Multicenter Real-World Analysis.

  P Lopedote

• 12:00 PM - 12:15 PM
  A whole-food plant-based diet restricts oncogenic kinase signaling and reduces leukemic burden in early-stage CLL patients

  M Knauer, A Herr

• 01:15 PM - 01:25 PM
  CLL13

  M Fürstenau

• 01:25 PM - 01:35 PM
  CLL14

  K Fischer

• 01:35 PM - 02:05 PM
  Proteogenomics: Identifying new molecular subgroups - translational data from CLL13 & CLL14

  T Oellerich, R Zahedi

• 02:05 PM - 02:15 PM
  CLL17

  O Al-Sawaf

• 02:15 PM - 02:25 PM
  CLL2000

  K Fischer

• 02:25 PM - 02:35 PM
  CLLRT1

  V Lipinsky

• 02:35 PM - 02:45 PM
  CLLRT2

  S Stilgenbauer

• 02:45 PM - 02:55 PM
  CLL16

  N Kutsch

• 02:55 PM - 03:05 PM
  CLL18

  P Cramer

• 03:25 PM - 03:35 PM
  CLLRR1

  O Al-Sawaf

• 03:35 PM - 03:45 PM
  CLLReVenG

  O Al-Sawaf

• 03:45 PM - 03:55 PM
  HO165 -Aether

  A Kater

• 03:55 PM - 04:05 PM
  CLLFrail2

  F Simon

• 04:05 PM - 04:15 PM
  CLL-Move (CLL15)

  P Langerbeins

• 04:15 PM - 04:25 PM
  CLL2-TaME

  R Lewis

• 04:25 PM - 04:35 PM
  NCT-CART20

  N Kutsch

• 04:55 PM - 05:05 PM
  On BCL2 inhibition and CLL

  MA Anderson

• 05:05 PM - 05:15 PM
  Richter Transformation

  E ten Hacken

• 05:15 PM - 05:25 PM
  Archetypes of clonal dynamics

  M Kwok

• 05:25 PM - 05:40 PM
  Discussion: Genomics and biology of CLL

  MA Anderson, E ten Hacken, M Kwok

• 05:40 PM - 06:10 PM
  Connecting the evidence: CLL data updates and their impact on treatment management

  S Stilgenbauer, S O'Brien

• 06:10 PM - 06:50 PM
  Flying dinner

• 06:50 PM - 07:00 PM
  YIM-Poster: Classification of 1,530 ATM Variants in CLL employing a Five-Factor Score derived from matched Non-Tumor Controls

  C Brey

• 07:00 PM - 07:10 PM
  YIM-Poster: Genome-wide profiling of mosaic chromosomal alterations identifies prognostic lesions and ancestry-associated heterogeneity in CLL

  R Griffin

• 07:10 PM - 07:20 PM
  YIM-Poster: Baseline Immune Phenotyping in Older (≥80 years) and Frail Patients with CLL: Associations with Infections, SPMs, and IGHV Status

  B M Mechtel

• 07:20 PM - 07:30 PM
  YIM-Poster: A novel combination of endocytosis inhibitor and CAR-T cells to enhance therapeutic efficacy against chronic lymphocytic leukemia

  M K Hasan

• 07:30 PM - 07:40 PM
  YIM-Poster: Development of novel microenvironment-driven patient-derived preclinical models of CLL

  V Klapp

• 07:40 PM - 07:50 PM
  YIM-Poster: Mathematical Modeling of Single-Cell Program–Driven State Transitions Predicts Ibrutinib Adaptive Resistance, Relapse Hazard, and Personalized Dosing Strategies in Chronic Lymphocytic Leukemia

  R Fajar

• 07:50 PM - 08:00 PM
  YIM-Poster: Lisocabtagene Maraleucel for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Outcomes in a Real-World Cohort

  J Huang

• 08:00 PM - 08:10 PM
  Introduction

  B Eichhorst

• 08:10 PM - 08:40 PM
  Keynote Lecture

  Elucidating genomic alterations in CLL and Richter's transformation

  E Campo

BALLONI Hallen | Ehrenfeldguertel 96 | 50823 Cologne

• 07:45 AM - 08:30 AM
  Check-In & Registration

• 08:00 AM - 08:30 AM
  CLL2000: Investigator meeting for participating study centers

  K Fischer

• 08:30 AM - 08:45 AM
  Welcome

  B Eichhorst

• 08:45 AM - 09:15 AM
  Current first-line considerations : Lessons from FLAIR and CLL17

  O Al-Sawaf, T Munir

• 09:15 AM - 09:25 AM
  MRD: Defining, detecting and quantifying

  A Rawstron

• 09:25 AM - 09:35 AM
  Outcome measures: What MRD can and cannot tell us

  B Wierda

• 09:35 AM - 09:50 AM
  Discussion: Novel concepts of CLL

  O Al-Sawaf, T Munir, A Rawstron, B Wierda

• 09:50 AM - 10:20 AM
  Fireside chat: The human side of CLL therapy: Shared decisions, patient preference and psychological outcomes

  J Förner, C Karamanidou

• 10:50 AM - 11:20 AM
  Transforming data into clinical practice - optimizing 1L treatment for CLL patients

  H Huber, A Tedeschi

• 11:20 AM - 11:30 AM
  Using degraders in CLL

  E Tausch

• 11:30 AM - 11:40 AM
  How to engage T-cells in hematological malignancies

  A Ramsay

• 11:40 AM - 11:50 AM
  T-cell-based therapies in CLL

  F Peters

• 11:50 AM - 12:05 PM
  Discussion: Novel strategies

  E Tausch, A Ramsay, F Peters

• 01:20 PM - 01:50 PM
  A decade of CLL therapy: From innovations to standards

  P Staber

• 01:50 PM - 02:20 PM
  Beyond undetectable - decoding MRD in CLL. Bridging individual - and trial-level surrogacy to inform clinical decisions

  M Ritgen, M Hoechstetter

• 02:20 PM - 02:30 PM
  Patient advocacy

  J Förner

• 02:30 PM - 02:40 PM
  Population registries to study outcomes and quality of life

  S Kersting

• 02:40 PM - 02:50 PM
  Leveraging Big Data to predict patient outcomes

  R Agius

• 02:50 PM - 03:05 PM
  Discussion: CLL, A lifelong Journey

  J Förner, S Kersting, R Agius

• 03:05 PM - 03:25 PM
  What we've learnt and where we are going?

  B Eichhorst, A Kater, B Wierda, J Brown, P Ghia

• 03:25 PM - 03:35 PM
  Closing remarks

  B Eichhorst